Drugmaker Hindustan Laboratories Files IPO Papers with SEBI to Fund Working Capital
Mumbai-headquartered Hindustan Laboratories has filed preliminary IPO papers with SEBI to raise funds through 50 lakh fresh shares and 91 lakh OFS shares. The pharmaceutical company operates under a B2G framework, manufacturing various therapeutic formulations and supplying to government institutions across 27 states and Union Territories.
*this image is generated using AI for illustrative purposes only.
Generic drug manufacturer Hindustan Laboratories has filed preliminary papers with capital markets regulator SEBI to raise funds through an initial public offering to meet working capital requirements. The Mumbai-headquartered company's maiden public offering represents a significant step in its growth trajectory as it seeks to access public capital markets.
IPO Structure and Fund Utilization
The IPO comprises two key components as outlined in the draft red herring prospectus. The offering includes both fresh capital raising and promoter stake dilution through an offer for sale mechanism.
| Component: | Share Count |
|---|---|
| Fresh Issue | 50 lakh shares |
| Offer for Sale (OFS) | 91 lakh shares |
| Total Offering | 1.41 crore shares |
The company plans to utilize proceeds from the fresh issue specifically for funding working capital requirements and general corporate purposes. This capital infusion is expected to support the company's operational expansion and business development initiatives.
Business Operations and Market Presence
Headquartered in Mumbai, Hindustan Laboratories operates as an Indian pharmaceutical company with a focused business model. The company specializes in large-scale manufacturing and supply of generic medicines, primarily serving government institutions under a business-to-government framework.
During the six months ended September 30, 2025, the company demonstrated significant geographic reach by supplying products across India to 27 states and Union Territories. This extensive distribution network highlights the company's established presence in the government pharmaceutical supply chain.
Product Portfolio and Manufacturing Capabilities
The company maintains a comprehensive product portfolio spanning multiple therapeutic categories and dosage forms. These offerings cater to both acute and chronic healthcare requirements across various medical conditions.
| Product Category: | Details |
|---|---|
| Dosage Forms | Tablets, capsules, liquid orals, ointments, powders |
| Therapeutic Areas | Anti-allergic, anti-diabetic, anti-infectives, cardiac care |
| Specialized Products | Anti-malarial, antiparasitic, gastro-intestinal medications |
| Healthcare Supplements | Nutritional, mineral, and vitamin supplements |
Investment Banking Arrangement
Choice Capital Advisors has been appointed as the book-running lead manager for the IPO. The investment banking firm will oversee the public offering process and coordinate with regulatory authorities and potential investors throughout the listing journey.
20
